Clinicians often face complex challenges when autoimmune conditions coexist or emerge during treatment. A recent case report highlights the successful use of JAK1 inhibition for alopecia in a 55-year-old woman with rheumatoid arthritis (RA). While her RA was well-controlled on golimumab and leflunomide, she developed progressive, non-scarring alopecia areata (AA). This clinical paradox occurs rarely with TNF-alpha inhibitors, necessitating a strategic shift in systemic therapy.

Challenges with Traditional Therapy

Initially, the patient received serial intralesional triamcinolone injections over 14 months. Despite these efforts, her Severity of Alopecia Tool (SALT) score worsened from 20 to 50. This progression occurred while she continued her TNF-alpha inhibitor therapy. Consequently, the failure of standard corticosteroids prompted the medical team to consider alternative pathways to manage the worsening hair loss. They recognized that continuing the current regimen would likely lead to further hair loss.

Efficacy of JAK1 Inhibition for Alopecia

To address both her RA and the emerging AA, doctors switched her treatment to upadacitinib. They escalated the dose from 15 mg to 30 mg to optimize the response. Remarkably, the patient showed visible hair regrowth within six weeks. Her SALT score improved to approximately 15 by the three-month mark. This rapid response suggests that selective JAK1 inhibition for alopecia provides a potent therapeutic option for refractory cases that do not respond to traditional anti-inflammatory agents.

Clinical Implications for Practice

This case underscores a pragmatic consideration for rheumatologists and dermatologists in India. Although spontaneous remission is possible, the temporal link strongly supports the efficacy of JAK1 inhibitors. Furthermore, these agents can manage multi-systemic autoimmune presentations simultaneously, which simplifies patient management. Physicians should remain vigilant for paradoxical hair loss during biologic therapy and consider switching to JAK inhibitors when conventional treatments fail to provide relief.

Frequently Asked Questions

Can TNF-alpha inhibitors cause alopecia?

Yes, while rare, some patients develop paradoxical alopecia areata while receiving TNF-alpha inhibitors like golimumab for other autoimmune conditions such as rheumatoid arthritis.

How does upadacitinib help in alopecia areata?

Upadacitinib blocks the JAK-STAT signaling pathway, specifically inhibiting JAK1. This action disrupts the inflammatory cytokine cycle that causes the immune system to attack hair follicles, allowing for regrowth.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

Nkala MB et al. Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition. J Dermatolog Treat. 2026 Dec undefined. doi: 10.1080/09546634.2026.2663647. PMID: 42089250.

King B, et al. Efficacy and Safety of Upadacitinib in Adults and Adolescents with Severe Alopecia Areata: Results from Replicate Phase 3 Trials. Lancet. 2024.

Pathak D, et al. Role of JAK Inhibitors in Alopecia Areata: A Literature Review. Indian Dermatol Online J. 2023;14(4):460-466.